Company / Cash & Equivalents
Moleculin Biotech, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.9M
FY2025
5-year range
$4.3M / $70.9M
FY2021-FY2025
Trend
+107.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents returned to growth in FY2025 after 3 years of decline, reaching $9M.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of -10.2%.
Declined from $24M to $9M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -41.0%
- 5-Year CAGR
- -10.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.2%, indicating a declining trend.
- In FY2025, cash & equivalents increased 107.5% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.9M | +107.5% |
| FY2024 | $4.3M | -81.8% |
| FY2023 | $23.6M | -45.4% |
| FY2022 | $43.1M | -39.1% |
| FY2021 | $70.9M | +367.3% |
| FY2020 | $15.2M | +41.3% |
| FY2019 | $10.7M | +50.5% |
| FY2018 | $7.1M | +42.5% |
| FY2017 | $5.0M | +17724.2% |
| FY2016 | $28.1K | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026